Exenatide
Also known as Byetta, Bydureon
Exenatide (Byetta/Bydureon) was one of the first GLP-1 diabetes injections — it lowers blood sugar and curbs appetite. The original is twice-daily; the extended-release version is weekly.
One-dose burn-down
Half-life
2.4 h
Tmax
2.1 h
Bioavailability
65%
Steady state
~1d
Typical dose
5 mcg
Short-acting GLP-1 receptor agonist (Byetta, twice daily). Bydureon is an extended-release weekly form with very different PK.
Mechanism of action
Exendin-4 analog; GLP-1 receptor agonist resistant to DPP-4.
Byetta PK shown here; the Bydureon microsphere formulation behaves completely differently.
Track Exenatide for free
Log your doses and PeptideBuddy models Exenatide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free